PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
News|Articles|March 27, 2018
Service Aids Design and Installation of Cleanroom Systems
Author(s)Pharmaceutical Technology Editors
Cleanroom floor and wall solutions from Sika meet rigorous standards for pharmaceutical manufacturing facilities.
A new service from Sika, a manufacturer of pharmaceutical floor and wall systems, will enable life sciences companies to assert greater control over the design, construction, maintenance, and cost of existing and new facilities. The company is making its network of technical, design, and construction experts available to architects, designers, and managers of pharmaceutical facilities to create systems that address the unique demands of pharma environments. Working along with Sika’s installation partners, companies can benefit from time-and cost-saving installation technology.
In applications for cleanrooms and other areas requiring the most stringent environmental monitoring, Sika has developed a hygienic envelope system that integrates floors, walls and ceilings into a seamless, non-porous, chemical-resistant barrier. This technique facilitates the ease and speed of sanitization and prevents liquids from compromising the substrate which could create the possibility of back-side mold growth.
“Controlled spaces in biologics, pharmaceutical, medical device, and clean production facilities are subject to both local and global inspections against rigorous standards,” said Jim Hendley, Life Sciences Vertical Market Manager, Sika Corporation USA, in a press release. “At Sika, we believe it is essential to integrate the designer, manufacturer and facility manager in to a team, to understand these issues and provide a holistic, no-surprise, flooring and-importantly-full-envelope system that maintain performance expectations, sterility, and construction schedules.”
This approach ensures the facility owner has greater control over the performance of the system through its lifetime and prevents failures. Sika systems offer durability and longevity, with chemical, mechanical, and impact resistance.
Source:
Related to this article
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
AI can turn medical device risk management into a continuous signal.
Sanofi will transfer 20 mature medicines and three manufacturing sites to Cheplapharm for a 26.4% equity stake, closing by Q3 2027.
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
Christy Owings, Thermo Fisher, on why early supply chain partnership and site visits prevent costly eCOA and clinical trial delays.
This article explores the historical use of silicone oil in the performance of primary drug product packaging; design of experiment test results for selection of the cleaning agent and CCPs; assessment of visible residue limits and Fourier-transform infrared spectroscopy surface analysis; and setting health-based exposure limits for silicone oil using a non-uniform distribution model, and a previously published permitted daily exposure.